for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crispr Therapeutics AG

CRSP.O

Latest Trade

79.90USD

Change

1.92(+2.46%)

Volume

1,473,692

Today's Range

76.81

 - 

80.50

52 Week Range

76.71

 - 

220.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

Record redemption in Ark ETF sparks liquidity worries

A record half-billion dollar redemption from Ark Invest's flagship fund in a single day has led analysts to highlight the risks arising from the ETF's heavy exposure to illiquid stocks if outflows pick up pace.

Analysis: Pawz and UFOs: Thematic ETFs boom, drawing punters and concern

From cat food to cannabis, it's boom time for quirky ETFs offering the chance to punt on niche themes in fast-growth sectors, but their huge gains are unnerving some who see them as another price-inflated asset that may threaten market stability.

BRIEF-Crispr Therapeutics AG Says Public Offering Of 6.43 Million Common Shares Priced At $70.00 Per Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics Commencing Underwritten Public Offering Of $325 Mln Of Common Shares

* CRISPR THERAPEUTICS AG - COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $325 MILLION OF COMMON SHARES

BRIEF-Crispr Therapeutics And Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted To Ctx001™ For The Treatment Of Severe Hemoglobinopathies

* CRISPR THERAPEUTICS AND VERTEX PHARMACEUTICALS ANNOUNCE FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO CTX001™ FOR THE TREATMENT OF SEVERE HEMOGLOBINOPATHIES Source text for Eikon: Further company coverage:

Swiss stocks - Factors to watch on April 29

The Swiss blue-chip SMI was seen opening 0.5% higher at 9,985 points on Wednesday, according to premarket indications by bank Julius Baer.

BRIEF-Crispr Therapeutics Reports First Quarter 2020 Financial Results

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Supplementing Risk Factors On Form 10-K With Potential Impacts From Coronavirus

* CRISPR THERAPEUTICS AG - SUPPLEMENTING RISK FACTORS ON FORM 10-K WITH POTENTIAL IMPACTS FROM CORONAVIRUS PANDEMIC - SEC FILING Source text: https://bit.ly/3bHHC8s Further company coverage:

BRIEF-Crispr Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2019 Financial Results

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics - On Dec. 13, 2019, Crispr, Bayer, Casebia Entered Into Retirement Agreement

* CRISPR THERAPEUTICS - ON DEC. 13, 2019, CRISPR, BAYER, CASEBIA ENTERED INTO RETIREMENT AGREEMENT

IFR US ECM Weekly Wrap-up

WEEKLY TOTAL $9.6bn – IPO $993m – ABB/BLOCK $6.3bn – FOLLOW-ON $1.65bn – CB $705m Monday

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

BRIEF-CRISPR Therapeutics Announces Pricing Of Public Offering Of Common Shares

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

BRIEF-CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE POSITIVE SAFETY AND EFFICACY DATA FROM FIRST TWO PATIENTS TREATED WITH INVESTIGATIONAL CRISPR/CAS9 GENE-EDITING THERAPY CTX001 FOR SEVERE HEMOGLOBINOPATHIES

BRIEF-CRISPR Therapeutics Reports Q3 Earnings Per Share $2.40

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics And Bayer Announce Update On Casebia Therapeutics

* CRISPR THERAPEUTICS AND BAYER ANNOUNCE AN UPDATE ON CASEBIA THERAPEUTICS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up